You can buy or sell PTGX and other stocks, options, ETFs, and crypto commission-free!
Protagonist Therapeutics, Inc. engages in the research and development of novel constrained peptide-based drug candidates that address significant unmet medical needs. Its product pipeline include PTG-300, PTG-200, and PN-943 The company was founded by Mark L. Read More Smythe on August 22, 2006 and is headquartered in Newark, CA.
52 Week High
52 Week Low
— per share
Expected May 6, After Hours